Others prefer morning injections so they can take advantage of the appetite suppression during waking hours
Mark Donowitz, Professor of Medicine and Physiology at Johns Hopkins, has stated regarding GLP-1 agonist patients: "Any medication that independently reduces GI motility should be used with caution in patients already experiencing delayed gastric emptying from incretin-based therapies." The Endocrine Society's 2023 Clinical Practice Guideline on pharmacologic management of obesity recommends reviewing all concomitant medications for GI side-effect overlap when initiating GLP-1 receptor agonist therapy [11]
Conclusions and Future Perspectives Overall, GLP-1RAs are considered novel blood glucose lowering drugs used in the treatment of T2MD (229), owing to their advantages of lowering blood pressure, lowering the levels of fasting blood glucose, lowering HbA1c, inducing weight loss, and being associated with a low incidence of hypoglycemia
Before starting semaglutide or tirzepatide, let your provider know if you: Have or have had pancreatitis or gallbladder disease, including gallstones